Suvratoxumab

Suvratoxumab is a fully human IgG1 monoclonal antibody developed for the prevention of nosocomial pneumonia, particularly ventilator-associated bacterial pneumonia (VAP), caused by Staphylococcus aureus, including both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains[1][5][6]. It specifically targets and neutralizes the *S. aureus* alpha toxin (also known as alpha hemolysin or AT), a key virulence factor responsible for host cell destruction during infection[1][6][8]. By binding to this toxin, suvratoxumab prevents its interaction with the cellular receptor ADAM10, thereby protecting host immune cells from cytotoxic effects[5][6]. The drug was originally developed by MedImmune/AstraZeneca and has since been licensed to Aridis Pharmaceuticals for further development[3][6]. Clinical trials have evaluated its efficacy in ICU patients colonized with *S. aureus*; while phase 2 results showed a reduction in pneumonia incidence among treated patients, subsequent development has been suspended as of late 2024[7].

Brand names

suvratoxumab

Other names

suvratoxumabMEDI4893MEDI-4893MEDI 4893AR-320AR320AR 320